TITLE:
Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy

CONDITION:
Rheumatoid Arthritis

INTERVENTION:
CCI-779

SUMMARY:

      The primary objective of this study is to compare the therapeutic response and safety of 3
      oral dose levels of CCI-779, with placebo in subjects with active rheumatoid arthritis (RA)
      who have been receiving stable doses of methotrexate (MTX) for at least 8 weeks.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion Criteria:

          -  Meet American College of Rheumatology (ACR) criteria for RA

          -  Have active RA consisting of  6 swollen and  6 painful joints

          -  ACR functional class I-III

        Exclusion Criteria

          -  At screening the subject's prior medications are reviewed. (Prior history of
             disease-modifying antirheumatic drug (DMARD) use is recorded, including the start and
             stop dates of the most recently taken DMARDs)

          -  Significant concurrent medical diseases

          -  Abnormal chest radiograph, including findings consistent with interstitial
             pneumonitis, granulomatous disease, or pleural effusion and/or infiltration
      
